dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Operating Room Homepage

Leading vascular surgeon presents comparative data analysis on EndoAVF procedures at Society of Interventional Radiology 2019

Synaptive Medical reveals automated white matter segmentation feature for Modus Plan Surgical planning tool

Stryker features new Spinemap Go software at the American Association Of Neurological Surgeons annual meeting this week

Stryker showcases new Sonopet iQ Ultrasonic Aspirator System at the American Association of Neurological Surgeons annual meeting

EOS imaging introduces EOSlink

Surgical Theater debuts a new approach to patient engagement utilizing augmented reality with magic leap

Elucent Medical receives FDA clearance for innovation for breast tumor removal procedures

Surgical Theater debuts precision Virtual Reality Enterprise Solution at DMEA in Berlin

Ethicon launches global registry to collect real-world data on liver lesions ablated with the Neuwave Microwave Ablation System

Study finds lower death rates for TAVR centers that do more procedures

MU orthopaedic surgeon begins FDA-approved study for novel knee-cartilage implant

Press releases may be edited for formatting or style
COLUMBIA, Mo. (February 4, 2019) ― Seth L. Sherman, MD, a sports medicine orthopaedic surgeon at University of Missouri Health Care's Missouri Orthopaedic Institute, recently became one of the first American surgeons to enroll patients in a clinical research study aimed at earning FDA approval for a new knee-cartilage implant.

Agili-C™ (CartiHeal, Israel) is a new implant designed to help patients with knee-cartilage defects regenerate their own healthy cartilage. The implant has been shown to be safe and effective in a series of clinical trials previously conducted in Europe and Israel. Sherman is one of 15 primary investigators in the United States conducting the FDA-approved study, which is the final step before earning FDA approval for the implant.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



"We are thrilled to be on the leading edge of orthopaedic sports medicine and joint preservation," Sherman said. "In the U.S., there are limited options for off-the-shelf cartilage repair that can be performed during a single surgical procedure. Benefits of this technology include its relative low cost, ease of use, and strong basic science and clinical track record."

Cartilage damage is a common knee problem that occurs in patients of all ages. It can happen as a result of an injury, like a blow to the knee, or due to wear and tear over time. In any case, it causes knee swelling, stiffness and pain that can reduce function and decrease quality of life.

The Agili-C™ implant is a cell-free implant made of the inorganic exoskeleton of sea coral. The implant can be used in this study to treat a variety of cartilage defects and patient types, which is another reason it is attractive to orthopaedic surgeons.

"Often in studies like this one, we can enroll only a very strict subset of young, active patients with a single, isolated cartilage defect," said Sherman. "In reality, that's not the type of patient we see every day. This implant is different because it's medically indicated for a wide range of situations, including patients with multiple cartilage defects and even those with mild to moderate osteoarthritis. We can use it in patients who are in their 20s or in those who are in their 60s. This versatility allows us to find more patients who may benefit from this procedure."

Those who qualify for the study are randomly assigned either one of the traditional surgical options or the new implant. So far, Sherman has enrolled four patients in the study. He plans to enroll at least 25 before submitting his research to the FDA.

The implant is manufactured by CartiHeal, a medical device company headquartered in Kfar Saba, Isreal and Closter, New Jersey. To date, more than 400 patients in Europe and Israel -- where the device has already been approved -- have received the new implant. The Agili-CTM implant is not available for sale in the United States. It is an investigational device limited for use in the device study.

Operating Room Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED